Attention from doctors to hospitals all around the world! Open Access Medical Journal will have an awesome article on oncotarget and the oncology field. This article is going to be huge! So calling all researchers as well! I urge you to purchase a copy of Open Access Medical Journal in December of 2017. The article will take your breath away!
This great article will touch briefly on pathologists, hematologists and the very important oncologist. Medical research has taken on a new meaning with these doctors. Hospitals and clinics have advanced so much in recent years. The doctors who were interviewed for our article had a lot of enthusiastic feedback once they saw the difference this article will make! That’s exactly what we are aiming to do – make a positive difference in peoples lives who are battling cancer and read full article.
High-Tech equipment, medicine, and great and doctors have been able to reduce some tumors in size! This gives the patient a fighting chance! A new sunny day of hope! Our digital article will wow you with great content and Oncoatarget’s lacrosse camp. Any doctor who reads it won’t be able to put it down! A spread of colorful photographs will make an appearance as well. These great pictures will range from tumors to doctors equipment and doctors themselves! What highly well trained doctor or nurse wouldn’t want a copy of this article and learn more about Oncotarget?
With cutting edge new exciting technology and hard work will make this a better world! We found the best author to write our article. Don’t forget to pick up your copy in December 2017. Open Access Medical Journal will hit store shelves November 28, 2017 and what Oncotarget knows.
More Visit: www.scijournal.org/impact-factor-of-ONCOTARGET.shtml
In a time where scientific discovery needs to be promoted and published, the world needs more free-access journals. Journals that publish new breakthroughs in science. Oncotarget is a free-access, multidisciplinary peer-reviewed journal on the forefront of science, not just oncology. Oncotarget began as a journal focusing on the pathological basis of all cancers. Their goal started off as presenting new information on the discovery of potential targets for therapy and new treatment protocols to help cancer patients.
The journal also focused on different management programs that improved patients quality of life, adherence, and satisfaction. Now, Oncotarget has branched out and opened their doors to topics beyond oncology. Papers on neuroscience, endocrinology, cardiology, metabolism, cell biology, and pharmacology are all welcome. By breaking down its barriers for its publication, Oncotarget has bridged the gaps between the different disciplines in biomedical science. This makes Oncotarget a more rounded and impactful journal.
It is a place for all scientists to come and get breaking news on the new scientific discoveries being made across the globe. It is important for scientific discoveries to go through the rigorous peer-review process. This is the fundamental part of the scientific method that keeps science honest and helps scientists build on the discoveries of their peers and mentors. It’s important for journals to have knowledgeable and fair leadership. Now more than ever we need a journal with honest reviews and steadfast morals. Oncotarget is at the forefront of discovery. Not just for oncology, but now for all of biomedical science.
When a serious health crisis struck the Lefkofsky family, it inspired Eric Lefkofsky to utilize his technological expertise in conjunction with entrepreneurial innovation to develop a strategic approach to improving the outcomes for those fighting the dreaded diseases of cancer. Through his co-founded biotechnology company Tempus, he teamed up with geneticist Kevin White, President of Tempus to create a centralized operating system that gathers and analyzes genomic and clinical data that enables oncologists to implement more personalized cancer treatment options for their patients.
The Tempus operating system eliminates some of the overwhelming frustrations and uncertainty associated with cancer disease by providing doctors and patients with valuable decision-making information. Cancer treatments and methods exist in a fluid environment. Tempus makes it possible to access pertinent data presented in a coherent fashion in a timely manner that could improve the quality of life, prolong life, or ultimately cure cancer disease.
Eric Lefkofsky has founded and/or cofounded several companies with a common focus on various aspects of technology throughout his entrepreneurial career. He has creatively explored applications of technology in a variety of creative innovations. In 2015 he co-founded Tempus, Inc. and serves as its Chief Executive Officer. In addition, he co-founded Uptake in 2014, a predictive analytics company that optimizes performance while simultaneously maximizing productivity on a global scale. He founded MediaBank in 2006 which merged with Donovan data Systems in 2012. The merger resulted in the creation of Mediaocean, a media platform that organizes the full-scope of advertising processes for over 80,000 advertising professionals nationally.
He has delved into private equity financing as a venture capitalist in his role as the co-founder of Lightbank. Mr. Lefkofsky has invested in over 70 small, early-stage, and/or emerging disruptive technology companies that are deemed to have high growth potential located throughout the United States. Lightbank is a Chicago-based venture capital firm. Eric Lefkofsky has packed a lifetime of adventure in the span of little more than a decade, but his vision has yet to end. He continues to push a path forward diligently seeking the next great opportunity to innovate unique solutions.
http://lefkofskyfoundation.com for more.